Lab testing of tumor samples to choose the next treatment in metastatic breast cancer
Tests whether lab-tested tumor samples can guide treatment in hormone receptor-positive metastatic breast cancer.
Key facts
- Who runs it
- Tel-Aviv Sourasky Medical Center
- Where
- Tel Aviv, IsraelSee the site
- Trial code
- Registry title
- Organ Culture for Endocrine Resistant Next Line: A Treatment Selection Study in Metastatic Breast Cancer
- Status
- Recruiting
- People taking part
- 39 people, planned
- Started
- 14 Jun 2024
- Expected to end
- 31 Dec 2029
- Type of study
- Interventional
- Treatments tested
- cResponse Ex Vivo Organ Culture (EVOC) Drug Sensitivity Assay
- Record updated
- 26 October 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with hormone receptor-positive, HER2-negative metastatic breast cancer that has grown during endocrine therapy. A fresh tumor sample is tested in the lab to help choose the next treatment.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- Metastatic breast cancer that has progressed on endocrine therapy, with or without biological therapy. The person is a candidate for a first treatment line that is not endocrine-based.
- Earlier treatment
- Must have progressed on endocrine therapy. Must not have had chemotherapy within 3 weeks before the biopsy or aspiration. Must not have taken another investigational drug within 14 days before study entry.
Main reasons for not taking part
- Chemotherapy within 3 weeks before biopsy or aspiration
- Positive test for AIDS
- Positive hepatitis B or hepatitis C test showing acute or chronic infection
- Pregnancy or breastfeeding
- Another investigational drug within 14 days before study entry
The registry criteria, word for word
Show all 12 criteriaShow less
Who can take part
- Patients progressing on endocrine therapy, with or without biological therapy, who are candidates for their first non-endocrine-based line of treatment
- Patients expected to receive treatment for metastatic breast cancer within the coming weeks
- Age 18 years or older
- Life expectancy of at least 3 months
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
Who cannot take part
- Chemotherapy within 3 weeks before biopsy or aspiration
- Any severe concurrent disease that, in the investigator's judgment, makes the patient unsuitable for study participation
- Treatment with another investigational drug within 14 days before study entry
- Positive test for acquired immunodeficiency syndrome (AIDS)
- Positive hepatitis B or hepatitis C testing indicating acute or chronic infection
- Pregnancy or breastfeeding
- Inability to exercise judgment
Where in Israel
- Tel-Aviv Sourasky Medical CenterTel Aviv, IsraelContact: Breast Cancer Research CoordinatorTaking people
About the trial
What the trial wants to find out
This study evaluates whether testing fresh tumor samples outside the body can help guide treatment selection for patients with hormone receptor-positive, HER2-negative metastatic breast cancer that has progressed during endocrine therapy.
Read full original descriptionShow less
A biopsy sample from each participant will be tested using an ex vivo organ culture (EVOC) platform, which preserves the tumor tissue and allows researchers to assess its response to different anticancer treatments. The results will be used to help select the participant's next systemic treatment.
The main objective is to evaluate the proportion of patients whose cancer responds to treatment selected using this approach. The study will also assess how long the cancer remains controlled, overall survival, and the relationship between laboratory test results and clinical outcomes.
The group in the trial
- EVOC-Guided Treatment SelectionTreatment being tested
Participants with endocrine-resistant metastatic breast cancer will undergo tumor biopsy and functional drug sensitivity testing using the cResponse ex vivo organ culture (EVOC) platform. The next systemic anticancer treatment will be selected based on the assay results, with preference for the highest-scoring clinically available treatment.
Treatment: cResponse Ex Vivo Organ Culture (EVOC) Drug Sensitivity Assay
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- OCEAN: Organ Culture for Endocrine Resistant Next Line - Treatment Selection Based on Fresh Tumor Samples in Metastatic Breast Cancer
- Plain-language title
- Lab testing of tumor samples to choose the next treatment in metastatic breast cancerGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 26 October 2026